Phase Ib Trial of Frontline Anti-CD47 Antibody Magrolimab + Azacitidine in TP53-Mutated AML

Source: 2022 ASCO Annual Meeting*
Download Slideset
June 3-7, 2022; Chicago, Illinois
In this single-arm study, magrolimab plus azacitidine had a tolerable safety profile and achieved a CR rate of 33% in the frontline treatment of patients with TP53-mutated AML not eligible for intensive induction therapy.
Format: Microsoft PowerPoint (.ppt)
File Size: 154 KB
Released: June 10, 2022

Acknowledgements

Provided by Clinical Care Options, LLC
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AbbVie
AstraZeneca
Gilead Sciences, Inc.
Merck Sharp & Dohme Corp.
Novartis Pharmaceuticals Corporation
Seagen

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings